Literature DB >> 25625024

PET imaging of apoptosis in tumor-bearing mice and rabbits after paclitaxel treatment with (18)F(-)Labeled recombinant human His10-annexin V.

Haidong Qin1, Ming-Rong Zhang2, Lin Xie2, Yanjie Hou1, Zichun Hua3, Minjin Hu4, Zizheng Wang1, Feng Wang5.   

Abstract

Monitoring response to chemo- or radiotherapy is of great importance in clinical practice. Apoptosis imaging serves as a very useful tool for the early evaluation of tumor response. The goal of this study was PET imaging of apoptosis with (18)F-labeled recombinant human annexin V linked with 10 histidine tag ((18)F-rh-His10-annexin V) in nude mice bearing an A549 tumor and rabbits bearing a VX2 lung cancer after paclitaxel therapy. (18)F-rh-His10-annexin V was prepared by conjugation of rh-His10-annexin V with N-succinimidyl 4-[(18)F]fluorobenzoate. Biodistribution was determined in mice by the dissection method and small-animal PET. Single-dose paclitaxel (175 mg/m(2)) was used to induce apoptosis in A549 and VX2 tumor models. (18)F-rh-His10-annexin V was injected into A549 mice and VX rabbits to acquire dynamic and static PET images 72 h after paclitaxel treatment. The uptake of (18)F-rh-His10-annexin V in apoptotic cells 4 h after induction was 6.45±0.52 fold higher than that in non-induced cells. High focal uptake of (18)F-rh-His10-annexin V was visualized in A549 (SUVmax: 0.35±0.13) and VX2 (0.41±0.23) tumor models after paclitaxel treatment, whereas lower uptake was found in the corresponding tumors before treatment (A549 SUVmax: 0.04±0.02; VX2: 0.009±0.002). The apoptotic index was 75.61±11.56% in the treated VX2 cancer, much higher than that in the untreated VX2 (8.03±2.81%). This study demonstrated the feasibility of (18)F-rh-His10-annexin V for the detection of apoptosis after chemotherapy in A549 and VX2 tumor models.

Entities:  

Keywords:  Apoptosis; molecular imaging; recombinant human His10-annexin V; tumor response

Year:  2014        PMID: 25625024      PMCID: PMC4299778     

Source DB:  PubMed          Journal:  Am J Nucl Med Mol Imaging


  33 in total

Review 1.  Objective responses in patients with malignant melanoma or renal cell cancer in early clinical studies do not predict regulatory approval.

Authors:  John Goffin; Stefan Baral; Dongsheng Tu; Dora Nomikos; Lesley Seymour
Journal:  Clin Cancer Res       Date:  2005-08-15       Impact factor: 12.531

2.  Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer.

Authors:  Norbert Avril; Stefanie Sassen; Barbara Schmalfeldt; Joerg Naehrig; Stephan Rutke; Wolfgang A Weber; Martin Werner; Henner Graeff; Markus Schwaiger; Walther Kuhn
Journal:  J Clin Oncol       Date:  2005-09-12       Impact factor: 44.544

3.  Revised response criteria for malignant lymphoma.

Authors:  Bruce D Cheson; Beate Pfistner; Malik E Juweid; Randy D Gascoyne; Lena Specht; Sandra J Horning; Bertrand Coiffier; Richard I Fisher; Anton Hagenbeek; Emanuele Zucca; Steven T Rosen; Sigrid Stroobants; T Andrew Lister; Richard T Hoppe; Martin Dreyling; Kensei Tobinai; Julie M Vose; Joseph M Connors; Massimo Federico; Volker Diehl
Journal:  J Clin Oncol       Date:  2007-01-22       Impact factor: 44.544

4.  Real-time imaging of apoptotic cell-membrane changes at the single-cell level in the beating murine heart.

Authors:  E A Dumont; C P Reutelingsperger; J F Smits; M J Daemen; P A Doevendans; H J Wellens; L Hofstra
Journal:  Nat Med       Date:  2001-12       Impact factor: 53.440

5.  Near-infrared fluorescent imaging of tumor apoptosis.

Authors:  Alexander Petrovsky; Eyk Schellenberger; Lee Josephson; Ralph Weissleder; Alexei Bogdanov
Journal:  Cancer Res       Date:  2003-04-15       Impact factor: 12.701

6.  Expression and purification of recombinant human annexin V in Escherichia coli.

Authors:  L N Zhang; X Yang; Z C Hua
Journal:  Prep Biochem Biotechnol       Date:  2000-11       Impact factor: 2.162

7.  Structural requirements for in vivo detection of cell death with 99mTc-annexin V.

Authors:  Jonathan F Tait; Christina Smith; Francis G Blankenberg
Journal:  J Nucl Med       Date:  2005-05       Impact factor: 10.057

8.  Imaging paclitaxel (chemotherapy)-induced tumor apoptosis with 99mTc C2A, a domain of synaptotagmin I: a preliminary study.

Authors:  Feng Wang; Wei Fang; Ming Zhao; Zizheng Wang; Shundong Ji; Yan Li; Yuming Zheng
Journal:  Nucl Med Biol       Date:  2008-04       Impact factor: 2.408

Review 9.  Role of 18F-FDG PET in assessment of response in non-small cell lung cancer.

Authors:  Rodney J Hicks
Journal:  J Nucl Med       Date:  2009-04-20       Impact factor: 10.057

Review 10.  In vivo detection of apoptosis.

Authors:  Francis G Blankenberg
Journal:  J Nucl Med       Date:  2008-06       Impact factor: 10.057

View more
  9 in total

Review 1.  The Continuing Evolution of Molecular Functional Imaging in Clinical Oncology: The Road to Precision Medicine and Radiogenomics (Part I).

Authors:  Tanvi Vaidya; Archi Agrawal; Shivani Mahajan; Meenakshi H Thakur; Abhishek Mahajan
Journal:  Mol Diagn Ther       Date:  2019-02       Impact factor: 4.074

Review 2.  Rabbit VX2 Liver Tumor Model: A Review of Clinical, Biology, Histology, and Tumor Microenvironment Characteristics.

Authors:  Florentina Pascale; Jean-Pierre Pelage; Michel Wassef; Saïda H Ghegediban; Jean-Pierre Saint-Maurice; Thierry De Baere; Alban Denys; Rafael Duran; Frédéric Deschamps; Olivier Pellerin; Noboru Maeda; Alexandre Laurent; Julien Namur
Journal:  Front Oncol       Date:  2022-05-10       Impact factor: 5.738

3.  Monitoring Cell Death in Regorafenib-Treated Experimental Colon Carcinomas Using Annexin-Based Optical Fluorescence Imaging Validated by Perfusion MRI.

Authors:  Philipp M Kazmierczak; Egon Burian; Ralf Eschbach; Heidrun Hirner-Eppeneder; Matthias Moser; Lukas Havla; Michel Eisenblätter; Maximilian F Reiser; Konstantin Nikolaou; Clemens C Cyran
Journal:  PLoS One       Date:  2015-09-22       Impact factor: 3.240

4.  Anti-cancer activity of Annexin V in murine melanoma model by suppressing tumor angiogenesis.

Authors:  Xuerui Zhang; Lina Huo; Haibo Jin; Yuheng Han; Jie Wang; Yanjun Zhang; Xinghuan Lai; Ziwei Le; Jing Zhang; Zichun Hua
Journal:  Oncotarget       Date:  2017-06-27

Review 5.  Avenues to molecular imaging of dying cells: Focus on cancer.

Authors:  Anna A Rybczynska; Hendrikus H Boersma; Steven de Jong; Jourik A Gietema; Walter Noordzij; Rudi A J O Dierckx; Philip H Elsinga; Aren van Waarde
Journal:  Med Res Rev       Date:  2018-03-12       Impact factor: 12.944

6.  Preliminary Study of a 1,5-Benzodiazepine-Derivative Labelled with Indium-111 for CCK-2 Receptor Targeting.

Authors:  Marco Verona; Sara Rubagotti; Stefania Croci; Sophia Sarpaki; Francesca Borgna; Marianna Tosato; Elisa Vettorato; Giovanni Marzaro; Francesca Mastrotto; Mattia Asti
Journal:  Molecules       Date:  2021-02-09       Impact factor: 4.411

7.  Establishment and evaluation of the VX2 orthotopic lung cancer rabbit model: a ultra-minimal invasive percutaneous puncture inoculation method.

Authors:  Lijuan Wang; Keke Che; Zhonghong Liu; Xianlong Huang; Shifeng Xiang; Fei Zhu; Yu Yu
Journal:  Korean J Physiol Pharmacol       Date:  2018-04-25       Impact factor: 2.016

8.  [18F]ML-10 PET: Initial Experience in Glioblastoma Multiforme Therapy Response Assessment.

Authors:  Matthew J Oborski; Charles M Laymon; Frank S Lieberman; Yongxian Qian; Jan Drappatz; James M Mountz
Journal:  Tomography       Date:  2016-12

9.  Clinical translation of [18F]ICMT-11 for measuring chemotherapy-induced caspase 3/7 activation in breast and lung cancer.

Authors:  S R Dubash; S Merchant; K Heinzmann; F Mauri; I Lavdas; M Inglese; K Kozlowski; N Rama; N Masrour; J F Steel; A Thornton; A K Lim; C Lewanski; S Cleator; R C Coombes; Laura Kenny; Eric O Aboagye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-09-27       Impact factor: 9.236

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.